Pfizer Can't Shake Investor Suit Over Off-Label Marketing
A New York federal judge refused Wednesday to dismiss a putative securities class action stemming from a $2.3 billion civil and criminal fine Pfizer Inc. paid for illegally marketing off-label uses...To view the full article, register now.
Already a subscriber? Click here to view full article